AstraZeneca UK’s president Lisa Anson is to take over the reigns of President of the Association of the British Pharmaceutical Industry.
Anson, who holds a MBA with distinction from INSEAD in France and a First Class degree in Natural Sciences from Cambridge University, has held a variety of senior management roles at AZ in both the US and the UK, following stints at an American healthcare firm and consultancy KPMG.
She joined the ABPI Board in January 2012, and has been engaged in a number of capacities since, leading on a number of key commercial projects such as implementing the UK’s Pharmaceutical Pricing Regulation Scheme (PPRS), which caps the total spend of branded medicines for the NHS.
Lisa will take over from current president John Kearney, General Manager at Amgen, from the end of April, and her time in the position will be very much focused on representing ABPI members during Brexit, and working with government to develop “a life-science strategy which puts the industry as a key strategic partner in the government’s future economic plans”, the Agency notes.
“During my term as president, our industry will face crucial issues including the UK’s departure from the European Union, ensuring biopharmaceuticals are central to the UK industrial strategy and leveraging a golden period of innovation in new medicines to ensure UK patients benefit,” Anson noted. “The ABPI is at the frontline of protecting and nurturing our relationship with government and the NHS, which will be vital to navigate these important issues.”
“The unanimous decision by the ABPI Board to elect Lisa Anson as President shows the esteem in which she is held,” said ABPI chief executive, Mike Thompson. “As a high profile president of AstraZeneca UK and Ireland her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry’s most challenging era to date.”
By Selina McKee
Source: Pharma Times
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
